UnknownPhase 1NCT04982146
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
Studying Pseudomyxoma peritonei
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
- Principal Investigator
- Lidia Rodríguez Ortiz, MDHospital Universitario Reina Sofía
- Intervention
- Bromelin(drug)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- Hospital Universitario Reina Sofía, Córdoba, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04982146 on ClinicalTrials.govOther trials for Pseudomyxoma peritonei
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328737One vs Three HIPEC Cycles After CRS for Pseudomyxoma PeritoneiBeijing Tsinghua Chang Gung Hospital
- RECRUITINGEARLY PHASE1NCT07341360Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma PeritoneiOslo University Hospital
- RECRUITINGNCT02073500Peritoneal Surface Malignancies - Characterization, Models and Treatment StrategiesOslo University Hospital